<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033652</url>
  </required_header>
  <id_info>
    <org_study_id>PREPS/2019/OM-01</org_study_id>
    <nct_id>NCT05033652</nct_id>
  </id_info>
  <brief_title>Impact on Mortality of Screening for Kidney Disease Associated With a Specialized Intervention During Hospitalization in a Territorial Hospital Trust</brief_title>
  <acronym>WARNING KD</acronym>
  <official_title>Impact on Mortality of Screening for Kidney Disease Associated With a Specialized Intervention During Hospitalization in a Territorial Hospital Trust</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kidney disease in its chronic or acute form shares many risk factors for initiation,&#xD;
      progression and prognosis with an increase in morbidity and mortality, the length of&#xD;
      hospitalization and the cost associated with stages of increasing severity. Its overall&#xD;
      estimated prevalence in the general population is 13% and 0.5% from stage 4, for which&#xD;
      referral to a nephrologist is recommended to reduce mortality, slow progression of renal&#xD;
      disease and better prepare for treatment by renal replacement. Acute kidney injury (AKI) is&#xD;
      defined as a sudden increase in serum creatinine (Scr) with a prognostic classification of&#xD;
      increasing severity. The population with chronic kidney disease (CKD) is often hospitalized&#xD;
      and is frequently complicated by AKI, however CKD is asymptomatic for a long time, requiring&#xD;
      structure screening in populations at risk.&#xD;
&#xD;
      Performing Scr assays during hospitalization is an opportunity to screen patients with severe&#xD;
      CRD or ARI requiring specialized treatment during and after hospitalization. A nephrological&#xD;
      opinion is recommended for patients with severe CKD and AKI.&#xD;
&#xD;
      Based on preliminary studies &quot;MRC GARD&quot; (NCT02938611) and &quot;ARI TARGET&quot; (NCT03192189), the&#xD;
      study investigators identified the frequency of patients with increased Scr corresponding to&#xD;
      stages ≥4 of CKD and to stage1b of ARI during their hospitalization. They found that 50% of&#xD;
      patients hospitalized with a severe AKI had a CKD prior to their hospitalization.&#xD;
&#xD;
      The use of dosages of Scr during hospitalization has been studied for AKI but without&#xD;
      targeting high-risk subgroups and with discordant results. The study investigators plan to&#xD;
      carry out a pragmatic study to show that an intervention combining alerts with Scr dosage to&#xD;
      detect severe forms of CRD and AKI during hospitalization associated with the systematic&#xD;
      intervention of a specialized dedicated team associating nephrologist and pharmacist to the&#xD;
      scale of a GHT will improve patient and renal survival 1 year after screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Cluster step wedge</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 Months</time_frame>
    <description>Information taken from national database</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for renal support</measure>
    <time_frame>12 Months</time_frame>
    <description>yes / no. Information available in the SNDS database and the REIN register.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Information taken from national database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency start of renal support management</measure>
    <time_frame>12 Months</time_frame>
    <description>Yes/no with exact date noted if yes. Information available in the REIN register</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oriented of patient towards autonomous support techniques</measure>
    <time_frame>12 Months</time_frame>
    <description>Yes/no. Information available in the REIN register</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Which autonomous support techniques used</measure>
    <time_frame>12 Months</time_frame>
    <description>renal transplant or home dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of an arteriovenous fistula during the first session</measure>
    <time_frame>12 Months</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of initial hospitalization</measure>
    <time_frame>12 Months</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of rehospitalizations</measure>
    <time_frame>12 Months</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causes of rehospitalizations</measure>
    <time_frame>12 Months</time_frame>
    <description>Information taken from SNDS database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients with stage ≥4 CKD followed by a nephrologist</measure>
    <time_frame>12 Months</time_frame>
    <description>Data-collection via the medical file on visit(s) to the nephrologist during hospitalization; after discharge from hospital via data collected in the SNDS database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with at least one inappropriate drug prescription for renal function</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with at least one inappropriate drug prescription for renal function</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with at least one inappropriate drug prescription for renal function</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of drug prescriptions slowing down the progression of the kidney disease and treating complications</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of drug prescriptions slowing down the progression of the kidney disease and treating complications</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of drug prescriptions slowing down the progression of the kidney disease and treating complications</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the incremental cost-efficiency ratio</measure>
    <time_frame>12 Months</time_frame>
    <description>ratio of la difference in cost and the difference in life expectancy between the two strategies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National scale estimation of costs avoided</measure>
    <time_frame>12 Months</time_frame>
    <description>Total costs of healthcare consumption and the cost of setting up the device in the two management strategies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the satisfaction carers of patients in the interventional group during hospitalization</measure>
    <time_frame>end of the interventional strategy phase (minimum 3 months, maximum 12 months)</time_frame>
    <description>6-item custom questionnaire on 5-point Likert scale with free comment section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the satisfaction doctors of patients in the interventional group during hospitalization</measure>
    <time_frame>end of the interventional strategy phase (minimum 3 months, maximum 12 months)</time_frame>
    <description>5-item custom questionnaire on 5-point Likert scale with free comment section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the satisfaction doctors of patients in the interventional group during hospitalization</measure>
    <time_frame>12 Months</time_frame>
    <description>5-item custom questionnaire on 5-point Likert scale with free comment section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient satisfaction of patients in the interventional group</measure>
    <time_frame>end of the interventional strategy phase (minimum 3 months, maximum 12 months)</time_frame>
    <description>3-item custom questionnaire on 5-point Likert scale free comment section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient satisfaction of patients in the interventional group</measure>
    <time_frame>12 months</time_frame>
    <description>3-item custom questionnaire on 5-point Likert scale free comment section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the implementation of the &quot;WARNING KD&quot; management model at individual facilities according to the Template for Intervention Description and Replication (TIDieR) checklist.</measure>
    <time_frame>Over the study - maximum 2 years</time_frame>
    <description>12-item checklist</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1680</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Standard strategy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Warning KD strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>WARNING KD</intervention_name>
    <description>Within 48h of detecting an abnormal creatinemia value (GFR&lt;30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the &quot;WARNING KD&quot; team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices.</description>
    <arm_group_label>Warning KD strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient or their representative must have given their free and informed consent&#xD;
             oral consent&#xD;
&#xD;
          -  The patient must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
          -  Patient living in the Gard, France&#xD;
&#xD;
          -  Patient with abnormal dose:&#xD;
&#xD;
               -  Severe grade 4 or 5 CKD suspected in front of a GFR &lt;30 mL / min / 1.73m2&#xD;
                  persisting during hospitalization.&#xD;
&#xD;
               -  Acute kidney injury &gt; stage 1 defined by an increase in serum creatinine of at&#xD;
                  least 100% in less than 7 days or a threshold greater than 354 µmol / l.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is participating in another category I interventional study, or is in a&#xD;
             period of exclusion determined by a previous study&#xD;
&#xD;
          -  It is impossible to give the subject or their representative informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  Patient is pregnant, parturient or breastfeeding.&#xD;
&#xD;
          -  Patient unable to express consent&#xD;
&#xD;
          -  Patient with Stage 1 Acute kidney injury defined by an increase in serum creatinine of&#xD;
             more than 26 µmol / l in less than 48 hours or a 50% increase in serum creatinine&#xD;
             within 7 days.&#xD;
&#xD;
          -  Patient with stage 1 to 3 CKD (glomerular filtration rate (GFR)&gt; 30 mL / min / 1.73m2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Moranne</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Moranne</last_name>
    <phone>04.66.68.31.49</phone>
    <email>olivier.moranne@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Alès Cévennes</name>
      <address>
        <city>Alès</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sad Gaizi</last_name>
      <phone>04.66.78.32.03</phone>
      <email>dr.gaizi@ch-ales.fr</email>
    </contact>
    <investigator>
      <last_name>Sad Gaizi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florent Broussous</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Bastide</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Sirvain</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Bibot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaut Fraisse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice Ray</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hicham Mouyazek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Marty</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Bagnols-sur-Cèze</name>
      <address>
        <city>Bagnols-sur-Cèze</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Michel Courrege</last_name>
      <phone>04.66.79.10.11</phone>
      <email>jmcourrege@ch-bagnolssurceze.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel Courrege</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Benoit</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Gnonko</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémy Torrogressa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea-Cristina Favre Varadi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Moranne</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clarisse Roux-Marson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain Genregrandpierre</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cédric Leguillou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Cayla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Pouderoux</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie Guedj</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Jourdan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie Ray</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine Houede</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Kouyoumdjian</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Droupy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Lumbroso</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

